

Independent Medical Education Grants

1st Jan 2018 – 31th Mar 2018

Sanofi US and its affiliate Genzyme Corporation are committed to supporting independent medical education activities in therapeutic areas in which the Company is involved, for healthcare professionals, patients, and consumers to improve patient care and health outcomes in therapeutic areas in which the Company is engaged. Sanofi US and Genzyme Corporation are part of the Sanofi Group, a global pharmaceutical company.

| Recipient Name(s) ¹ | Activity Title | Funding Amount ² |
|--|---|-----------------------------|
| University of Kansas Continuing Education & Professional Development | 2017 Muscle Study Group Scientific annual Meeting- Neuromuscular Therapeutics: Bench to Bedside and Beyond | 25,000 |
| National Jewish Health PVI Peerview institute for Medical Education Inc. | PeerView inPlay and inClinic: “Optimizing Asthma Control Through Accurate Identification, Evidence-Based Management and Targeted Therapeutic Options” | 209,000 |
| Aventura Hospital | Miami Thyroid Oncology Symposium | 10,000 |
| AcademicCME, LLC. | ASCO GU 2018: A Clinical Analysis of Optimal Therapeutics to Improve Outcomes in Patients with Prostate Cancer | 82,300 |
| The Medical College of Wisconsin, Inc. PVI, PeerView Institute for Medical Education, Inc | PeerView Live at BMT 2018, “Integrated Myeloma Management & Enhanced Patient Outcomes: The Conjunction of Novel Therapeutic Platforms, Innovative Agents, and Stem Cell Transplant” | 88,555 |
| American Society of Transplant Surgeons | 18th Annual State of the Art Winter Symposium The Future Is Now: Saving More Lives Through Transplantation | 75,000 |
| The Medical College of Wisconsin, Inc. Carden Jennings Publishing | Optimal Use of Stem Cell Mobilization in Patients with Multiple Myeloma and Non-Hodgkin’s Lymphoma | 305,000 |

¹ Applicant names are provided by the requestor. If applicants apply as a group for a single educational activity; all applicants may not be identified above. The Company funds other educational activities (including fellowships and non-physician and patient education); all of which do not appear on this report, but appear on other reports on this site.

² “Funding Amount” is the amount that the Company funded during Q1, 2018 identified above based upon an agreement. Recipients are required to return any unused funds. Information on unused funds returned by the applicant on activities are not reported. “Funding Amount” does not include funds that may have been provided by other affiliated Sanofi Company Entities, (e.g., Sanofi Pasteur)

³ Collaboration (Shared) Funding – is the full amount of a grant funded under an agreement with Regeneron, some or all of which may be shared between the collaborating entities.

⁴ Collaboration (Shared) Funding – is the full amount of a grant funded under an agreement with Lexicon, some or all of which may be shared between the collaborating entities.

Independent Medical Education Grants

1st Jan 2018 – 31th Mar 2018

| Recipient Name(s) ¹ | Activity Title | Funding Amount ² |
|---|--|-----------------------------|
| Medical Learning Institute PVI, PeerView Institute for Medical Learning | PeerView inReview, "Assessing the Potential Impact of New Consensus Recommendations and Ongoing Clinical Trials of Emerging Therapies on the Diagnosis and Treatment of Acid Sphingolmyelinase Deficiency" | 104,250 |
| National Society of Genetic Counselors (NSGC) | New Lysosomal Storage Disease Healthcare Advocate Workshop 2018 | 42,637 |
| American Society of Clinical Oncology, Inc. Conquer Cancer Foundation of the American Society of Clinical Oncology | 2018 Genitourinary (GU) Cancers Symposium: Translating Evidence to Multidisciplinary Care | 30,000 |
| American Association of Clinical Endocrinologists | Advances in Medical & Surgical Management of Thyroid Cancer | 15,000 |
| ScientiaCME LLC | Atopic Dermatitis (AD): Best Practices, Barriers to Care, and Emerging Therapies in Medication Management | 19,100 |
| Potomac Center for Medical Education Rockpointe Corporation | Risk-Benefit Analysis and Personalized Treatment in Multiple Sclerosis: Basing Treatment Goals on the Latest Evidence | 100,000 |
| Elsevier Office of Continuing Medical Education ASiM CE, LLC | Moving from Treating Atopic Dermatitis Symptoms to Treating Underlying Pathology | 165,000 |
| University of Cincinnati Advances in Cosmetics and Medical Dermatology | MauiDerm 2018 | 50,000 |
| Postgraduate Institute for Medicine | The Rheumatoid Arthritis Vital Education Initiative: New Horizons in Therapeutic Options (RAVE: New Horizons) | 264,800 |
| American Society for Blood and Marrow Transplantation | American Society for Blood and Marrow Transplantation New Investigator Award | 65,000 |

¹ Applicant names are provided by the requestor. If applicants apply as a group for a single educational activity; all applicants may be not be identified above. The Company funds other educational activities (including fellowships and non-physician and patient education); all of which do not appear on this report, but appear on other reports on this site.

² "Funding Amount" is the amount that the Company funded during Q1, 2018 identified above based upon an agreement. Recipients are required to return any unused funds. Information on unused funds returned by the applicant on activities are not reported. "Funding Amount" does not include funds that may have been provided by other affiliated Sanofi Company Entities, (e.g., Sanofi Pasteur)

³ Collaboration (Shared) Funding – is the full amount of a grant funded under an agreement with Regeneron, some or all of which may be shared between the collaborating entities.

⁴ Collaboration (Shared) Funding – is the full amount of a grant funded under an agreement with Lexicon, some or all of which may be shared between the collaborating entities.



Sanofi US, A SANOFI COMPANY

Independent Medical Education Grants

1st Jan 2018 – 31th Mar 2018

| Recipient Name(s) ¹ | Activity Title | Funding Amount ² |
|--|---|-----------------------------|
| UT Southwestern Medical Center | 40th Annual Carrell-Krusen Neuromuscular Symposium | 5,000 |
| Regents of the University of California | 6th Annual UC San Diego Essentials and Advances in Apheresis | 5,000 |
| Physicians' Education Resource | Multiple Sclerosis: A Treatment Paradigm Shift when Time is Brain | 85,100 |
| Physicians' Education Resource, LLC (PER) | 2018 New York GU™: 11th Annual Interdisciplinary Prostate Cancer Congress® | 50,000 |
| National Comprehensive Cancer Network | NCCN 23rd Annual Conference: Improving the Quality, Effectiveness, and Efficiency of Cancer Care™ | 25,000 |
| UNTHSC | Overcoming Persistent Barriers to Effective Management of Atopic Dermatitis | 72,500 |
| Cleveland Clinic Educational Foundation | 2018 Nephrology Update | 10,000 |
| Medical Learning Institute, Inc PVI, PeerView Institute for Medical Education, Inc. | PeerView in Session, "New Developments in Allergic and Inflammatory Diseases: Clinical Updates From San Diego and Orlando" | 168,730 |
| Penn State College of Medicine PVI, PeerView Institute for Medical Education Inc. | Science and Stories: Navigating the Prostate Cancer Landscape: Urologists at the Intersection of Emerging Evidence and Patient Centric Care | 90,000 |
| UMA Education Inc., dba Global Education Group | Cutting Edge of Transplantation 2018: Breaking through Regulatory Barriers to Unleash Transplant Innovation to Success | 40,000 |
| American Society of Transplantation | 2018 ACR Rheumatology Courses | 75,000 |
| American College of Rheumatology | Global Perspectives on Current and Emerging Biologic Therapies for Rheumatoid Arthritis | 151,341 |
| PRIME Education, LLC | | |
| The Medical College of Wisconsin, Inc. Carden Jennings Publishing Co., Ltd. | The 28th Annual International Prostate Cancer Update (IPCU 28) | 10,000 |
| NYU Post-Graduate Medical School | NYU Langone Seminar in Advanced Rheumatology | 20,000 |

¹ Applicant names are provided by the requestor. If applicants apply as a group for a single educational activity; all applicants may be not be identified above. The Company funds other educational activities (including fellowships and non-physician and patient education); all of which do not appear on this report, but appear on other reports on this site.

² "Funding Amount" is the amount that the Company funded during Q1, 2018 identified above based upon an agreement. Recipients are required to return any unused funds. Information on unused funds returned by the applicant on activities are not reported. "Funding Amount" does not include funds that may have been provided by other affiliated Sanofi Company Entities, (e.g., Sanofi Pasteur)

³ Collaboration (Shared) Funding – is the full amount of a grant funded under an agreement with Regeneron, some or all of which may be shared between the collaborating entities.

⁴ Collaboration (Shared) Funding – is the full amount of a grant funded under an agreement with Lexicon, some or all of which may be shared between the collaborating entities.

Independent Medical Education Grants

1st Jan 2018 – 31th Mar 2018

| Recipient Name(s) ¹ | Activity Title | Funding Amount ² |
|--|---|-----------------------------|
| AcademicCME, LLC. | Individualizing Treatment Plans to Reduce Disease Activity in Patients with Rheumatoid Arthritis | 75,000 |
| Physicians' Education Resource, LLC (PER) | Medical Crossfire®: Personalizing Care for Multiple Myeloma Patients: Current and Future Sequencing Strategies | 75,000 |
| American College of Surgeons | The changing face of thyroid cancer management for surgeons: real-life applications of the new ATA guidelines | 40,900 |
| Penn State College of Medicine | PeerView Live at ASCO 2018: "How I Think, How I Treat: A Personal Look at Innovative Therapy and Meeting Patient Needs in Multiple Myeloma" | 75,000 |
| PVI, PeerView Institute for Medical Education, Inc. | Evolving Management Strategies for Moderate-to-Severe Atopic Dermatitis: Looking Beyond Barriers to Optimized Therapy | 346,647 |
| UMA Education Inc., LLC dba: Global Education Group (GLOBAL) | Advances In™ Supportive Care: An Onco-Nurses Guide to Managing Cancer Treatment-Related Toxicities | 50,000 |
| Physicians' Education Resource, LLC (PER) | Exploring the Challenges of Severe Asthma: Implementing Personalized Treatment Plans for Improved Patient Outcomes | 45,000 |
| National Association of Managed Care Physicians | Conversations in Dermatology The Evolving Paradigm in Atopic Dermatitis: Integrating Evolving Treatments to Improve Outcomes | 59,000 |
| National Association for Continuing Education | Multiple Sclerosis Symposium 2018 | 5,000 |
| Eastern Virginia Medical School | Neuromuscular Review Course | 25,000 |
| University of Kansas Medical Center | Moving Toward Improved Outcomes in MS: How PAs Can Make a Difference | 50,000 |
| American Academy of Pas Medical Logix, LLC | | |

¹ Applicant names are provided by the requestor. If applicants apply as a group for a single educational activity; all applicants may not be identified above. The Company funds other educational activities (including fellowships and non-physician and patient education); all of which do not appear on this report, but appear on other reports on this site.

² "Funding Amount" is the amount that the Company funded during Q1, 2018 identified above based upon an agreement. Recipients are required to return any unused funds. Information on unused funds returned by the applicant on activities are not reported. "Funding Amount" does not include funds that may have been provided by other affiliated Sanofi Company Entities, (e.g., Sanofi Pasteur)

³ Collaboration (Shared) Funding – is the full amount of a grant funded under an agreement with Regeneron, some or all of which may be shared between the collaborating entities.

⁴ Collaboration (Shared) Funding – is the full amount of a grant funded under an agreement with Lexicon, some or all of which may be shared between the collaborating entities.

Independent Medical Education Grants

1st Jan 2018 – 31th Mar 2018

| Recipient Name(s) ¹ | Activity Title | Funding Amount ² |
|---|---|-----------------------------|
| Med-IQ, LLC | Preventing Tumor Lysis Syndrome: Risk Assessment and Appropriate Prophylaxis | 75,000 |
| Cleveland Clinic Educational Foundation | Cleveland Clinic Neurological Institute Summit 2018: MS Treatment Strategies | 50,000 |
| Johns Hopkins University School of Medicine | 14th Annual Advances in the Diagnosis and Treatment of the Rheumatic Diseases | 30,000 |
| National Association of Managed Care Physicians | Implementing Newer Biologic Therapies to Improve Economic and Clinical Outcomes in Patients with Moderate to Severe Atopic Dermatitis | 57,000 |
| Annenberg Center for Health Sciences at Eisenhower Dana Farber Cancer Institute | Master Class for Oncologists | 30,000 |
| Elsevier Office of Continuing Medical Education ASiM CE LLC Dannemiller | Rising to the Challenge: Diagnosis and Optimal Management of Atopic Dermatitis in the Primary Care Setting | 124,000 |
| National Association of Managed Care Physicians | Novel Treatment Advances and Approaches in Rheumatoid Arthritis: Personalizing Therapy for Improved Clinical and Economic Outcomes | 45,000 |
| National Kidney Foundation | Managing the Life-Long Impact of Fabry Disease | 265,995 |
| Annenberg Center for Health Sciences at Eisenhower PlatformQ Health Education, LLC | Optimal Treatment sequencing in Metastatic Castration-Resistant Prostat Cancer: Expert Analysis through Case Studies | 65,000 |
| Michael J Fox Foundation | MDS-PAS Movement Disorders School for Neurology Residents | 20,000 |
| Penn State College of Medicine PVI, PeerView Institute for Medical Education, Inc | Science and Stories at ASCO 2018: Making an Impact in Prostate Cancer – Using Expert Experience and Evidence to Personalize the Complex Treatment Landscape | 100,000 |

¹ Applicant names are provided by the requestor. If applicants apply as a group for a single educational activity; all applicants may not be identified above. The Company funds other educational activities (including fellowships and non-physician and patient education); all of which do not appear on this report, but appear on other reports on this site.

² “Funding Amount” is the amount that the Company funded during Q1, 2018 identified above based upon an agreement. Recipients are required to return any unused funds. Information on unused funds returned by the applicant on activities are not reported. “Funding Amount” does not include funds that may have been provided by other affiliated Sanofi Company Entities, (e.g., Sanofi Pasteur)

³ Collaboration (Shared) Funding – is the full amount of a grant funded under an agreement with Regeneron, some or all of which may be shared between the collaborating entities.

⁴ Collaboration (Shared) Funding – is the full amount of a grant funded under an agreement with Lexicon, some or all of which may be shared between the collaborating entities.

Independent Medical Education Grants

1st Jan 2018 – 31th Mar 2018

| Recipient Name(s) ¹ | Activity Title | Funding Amount ² |
|---|--|-----------------------------|
| Purdue University Clinical Care Options, LLC | Advancing Care in Prostate Cancer: Aligning Your Practice With Rapidly Evolving Standards of Care Throughout the Disease Continuum | 80,000 |
| Continuing Education Alliance | 2018 PCE Oncology Symposia Series Segment: Sequencing Therapy in Patients with Castration-Resistant Prostate Cancer | 125,000 |
| University of Chicago | At the Forefront of Hepatology | 5,000 |
| National Association of Managed Care Physicians | The Value of Personalized Treatment Sequencing for Castration-Resistant Prostate Cancer | 45,000 |
| Vindico Medical Education, LLC | Immunology Bootcamp | 100,000 |
| American Urological Association | 2018 Evidence-based Clinical Management of Advanced and Castration-Resistant Prostate Cancer | 100,000 |
| International Transplant Nurses Society | European Transplant Nursing Symposium | 10,000 |
| UMA Education Inc., dba Global Education Group FACTORx MedEd Consulting Improve CME, LLC NACE Pri-Med Indegene, Inc | R.A.P.I.D.®—Rheumatoid Arthritis: A Primary Care Initiative for Improved Diagnosis and Outcomes | 200,000 |
| Postgraduate Institute for Medicine | The Learning Pathway in Atopic Dermatitis: Maximizing Positive Outcomes for Your Patients | 362,310 |

¹ Applicant names are provided by the requestor. If applicants apply as a group for a single educational activity; all applicants may not be identified above. The Company funds other educational activities (including fellowships and non-physician and patient education); all of which do not appear on this report, but appear on other reports on this site.

² “Funding Amount” is the amount that the Company funded during Q1, 2018 identified above based upon an agreement. Recipients are required to return any unused funds. Information on unused funds returned by the applicant on activities are not reported. “Funding Amount” does not include funds that may have been provided by other affiliated Sanofi Company Entities, (e.g., Sanofi Pasteur)

³ Collaboration (Shared) Funding – is the full amount of a grant funded under an agreement with Regeneron, some or all of which may be shared between the collaborating entities.

⁴ Collaboration (Shared) Funding – is the full amount of a grant funded under an agreement with Lexicon, some or all of which may be shared between the collaborating entities.

Independent Medical Education Grants

1st Jan 2018 – 31th Mar 2018

| Recipient Name(s) ¹ | Activity Title | Funding Amount ² |
|---|--|-----------------------------|
| American Urological Association | AUA 2018 Highlights in Advanced and Castration-Resistant Prostate Cancer | 80,000 |
| PESI Inc. | 15th Annual World Congress on Insulin Resistance, Diabetes & Cardiovascular Disease | 50,000 |
| Horizon CME | Improving the Quality of Care in Patients with Diabetes through a Simulated QI Experience | 237,900 |
| Joslin Diabetes Center | Long-acting Insulins in Treatment of Type 2 Diabetes: Aligning Provider and Patient Perspectives to Address Therapeutic Barriers | 324,500 |
| Boston University School of Medicine Practicing Clinicians Exchange (PCE) | Balancing Glycemic Control and Hypoglycemia in T2DM: the Role of long-acting Basal Insulin Analogues | 435,000 |
| Physicians' Education Resource | Physiologic Insulin Replacement: Practical Strategies for Insulin Initiation and Titration of Long-Acting Insulins | 105,650 |
| University of Massachusetts Medical School CMEducation Resources | The Foundational role of Physiologic, long-acting Basal Insulin: Optimizing the safety-efficacy equation in vulnerable patients with T2D | 341,000 |
| Postgraduate Institute for Medicine CMEducation Resources | Targeting diabetic patients for Physiologic, long-acting Basal Insulin therapy- A best practice roadmap to clinical success | 496,200 |
| The Endocrine Society | Diabetes Masters Series 2018: Getting to the heart of the matter: Multidisciplinary perspectives on patient-centered care in T2DM | 249,885 |
| Institute for Medical and Nursing Education, Inc. | Leveraging CDEs to Improve Individualized Management of T2D: Focus on Injectable Therapies | 1,024,440 |

¹ Applicant names are provided by the requestor. If applicants apply as a group for a single educational activity; all applicants may not be identified above. The Company funds other educational activities (including fellowships and non-physician and patient education); all of which do not appear on this report, but appear on other reports on this site.

² "Funding Amount" is the amount that the Company funded during Q1, 2018 identified above based upon an agreement. Recipients are required to return any unused funds. Information on unused funds returned by the applicant on activities are not reported. "Funding Amount" does not include funds that may have been provided by other affiliated Sanofi Company Entities, (e.g., Sanofi Pasteur)

³ Collaboration (Shared) Funding – is the full amount of a grant funded under an agreement with Regeneron, some or all of which may be shared between the collaborating entities.

⁴ Collaboration (Shared) Funding – is the full amount of a grant funded under an agreement with Lexicon, some or all of which may be shared between the collaborating entities.

Independent Medical Education Grants

1st Jan 2018 – 31th Mar 2018

| Recipient Name(s) ¹ | Activity Title | Funding Amount ² |
|--|--|-----------------------------|
| Pharmacy Times Continuing Education | An American Journal of Managed Care Medical Crossfire: Evaluating New Generation Basal Insulin Therapy | 202,150 |
| American Association of Nurse Practitioners | The I's Have It: Improving Insulin Initiation Inertia A Nurse Practitioner-Led Quality Initiative | 358,557 |
| Pri-Med Institute, LLC | Newer Long-acting Insulins: A Physiologic Approach to Glucose Control | 721,504 |
| National Association for Continuing Education | Clinical Updates for NPs and PAs: 2018 - Advances in Insulin Therapy: Another Step Closer to a More Physiological Strategy | 244,585 |
| Institute for Medical and Nursing Education, Inc. | AAFP 2018: Building Basal Knowledge: Establishing a Solid Foundation for Using New Options in Basal Insulin for T2DM | 374,867 |
| NACCME, LLC | Incorporating Long-Acting Insulin Therapy into the Physiologic Approach to Diabetes Management | 180,565 |
| Postgraduate Institute for Medicine CMEducation Resources | Multi-Mechanistic, Insulin-Based Approaches for Achieving HA1c/PPG Targets and Optimizing Safety in Challenging Patients with T2D | 347,000 |
| Pharmacy Times Continuing Education | Emerging Strategies for the Safe and Effective Treatment of Uncontrolled Diabetes: The Application of Fixed Ratio Combination Insulin/GLP-1 RA Options | 81,303 |
| Boston University School of Medicine Practicing Clinicians Exchange | Type 2 Diabetes: New Treatment Combinations for Early and Aggressive Glucose Control | 870,000 |
| Postgraduate Institute for Medicine CMEducation Resources | Complementary insulin-based approaches for achieving HA1c/PPG targets and optimizing safety in patients with T2D: A best practice roadmap | 935,000 |

¹ Applicant names are provided by the requestor. If applicants apply as a group for a single educational activity; all applicants may be not be identified above. The Company funds other educational activities (including fellowships and non-physician and patient education); all of which do not appear on this report, but appear on other reports on this site.

² "Funding Amount" is the amount that the Company funded during Q1, 2018 identified above based upon an agreement. Recipients are required to return any unused funds. Information on unused funds returned by the applicant on activities are not reported. "Funding Amount" does not include funds that may have been provided by other affiliated Sanofi Company Entities, (e.g., Sanofi Pasteur)

³ Collaboration (Shared) Funding – is the full amount of a grant funded under an agreement with Regeneron, some or all of which may be shared between the collaborating entities.

⁴ Collaboration (Shared) Funding – is the full amount of a grant funded under an agreement with Lexicon, some or all of which may be shared between the collaborating entities.

Independent Medical Education Grants

1st Jan 2018 – 31th Mar 2018

| Recipient Name(s) ¹ | Activity Title | Funding Amount ² |
|--|--|-----------------------------|
| American Academy of PAs | Achieving Quality Measures in T2DM: Addressing Clinical Inertia and Patient Needs with Complementary Insulin-Based Therapies | 199,600 |
| National Association for Continuing Education | Clinical Updates for NPs and PAs: 2018 - Combination Basal Insulin and GLP-1 RA Therapy: A Physiologic Approach to Diabetes Care | 244,585 |
| North Carolina Academy of Family Physicians Med-IQ, LLC | Ready, set, action: An intervention to combat clinical inertia and reduce prolonged hyperglycemia in T2DM | 372,477 |
| Pharmacy Times Continuing Education | The Advent of Insulin/GLP-1 RA Fixed-Ratio Agents for Uncontrolled Diabetes: Moving Past the Barriers of Clinical Inertia | 129,020 |
| Pri-Med Institute, LLC | Treatment Intensification in T2DM: A Pathophysiologic Approach to Combining GLP-1 Receptor Agonists with Basal Insulin | 721,504 |
| American Association of Clinical Endocrinologists | Endocrine University: Lipids Module | 4,000 |
| Elsevier Office of Continuing Medical Education Integritas Communications | Raising the Bar by Lowering the Target: Integrating PCSK9 Inhibitors into Hypercholesterolemia Management | 419,083 |
| University of Tennessee College of Pharmacy | Breaking Barriers to Diabetes Control with GLP-1RA/ Insulin Combination Agents: Opportunities for the Community Pharmacist | 165,000 |
| American Association of Nurse Practitioners | Advances in Diabetes Management: Titratable Fixed-Ratio Combination Therapy and its Role in T2DM Treatment | 235,873 |
| University of California, San Diego | Comparing and Contrasting Basal Insulin Strategies in Type 1 and Type 2 Diabetes | 481,775 |

¹ Applicant names are provided by the requestor. If applicants apply as a group for a single educational activity; all applicants may not be identified above. The Company funds other educational activities (including fellowships and non-physician and patient education); all of which do not appear on this report, but appear on other reports on this site.

² “Funding Amount” is the amount that the Company funded during Q1, 2018 identified above based upon an agreement. Recipients are required to return any unused funds. Information on unused funds returned by the applicant on activities are not reported. “Funding Amount” does not include funds that may have been provided by other affiliated Sanofi Company Entities, (e.g., Sanofi Pasteur)

³ Collaboration (Shared) Funding – is the full amount of a grant funded under an agreement with Regeneron, some or all of which may be shared between the collaborating entities.

⁴ Collaboration (Shared) Funding – is the full amount of a grant funded under an agreement with Lexicon, some or all of which may be shared between the collaborating entities.

Independent Medical Education Grants

1st Jan 2018 – 31th Mar 2018

| Recipient Name(s) ¹ | Activity Title | Funding Amount ² |
|--|--|---------------------------------------|
| University of Massachusetts Medical School CMEducation Resources | The Mechanistic and Therapeutic Rationale for Dual SGLT1/2 Inhibition in Adults with Type 1 Diabetes | 342,750 Collaboration ⁴ |
| American Association of Clinical Endocrinologists Institute for Medical and Nursing Education, Inc. | AACE 2018 - Reflecting on the Data Pool: Emerging Roles for SGLT1 and SGLT2 Inhibition in T1DM | 357,151 Collaboration ⁴ |
| American Association of Diabetes Educators E&S MedEd Group, Inc. | Reducing Glycemic Variability in Type 1 Diabetes: An Exploration of Non-Insulin Treatment Options | 333,715 Collaboration ⁴ |
| Medscape LLC | Maximizing Medical Management of Knee Osteoarthritis: Use of Injectable Therapy | 174,500 |
| Oakstone Publishing, LLC. PeerVoice America Limited | Reducing Cardiovascular Risk in Patients With Dyslipidemia: What Do We Know Now? (And What Should We Do About It?) | 374,288 Collaboration ³ |
| Pharmacy Times Continuing Education | Managing Hypercholesterolemia: Clinical Updates for Specialty Pharmacists on PCSK9 Inhibitor Therapy | 85,201 Collaboration ³ |
| Postgraduate Institute for Medicine CMEducation Resources | The Landmark Evidence and Clinical Rationale for PCSK9 Inhibition in the diabetic patient | 486,800 Collaboration ³ |
| Preventive Cardiovascular Nurses Association | 2018 PCNA Dyslipidemia Campaign | 60,000 Collaboration ³ |
| Oakstone Publishing, LLC. PeerVoice America Limited | Modern Management of Lipid-Related Cardiovascular Risk in Patients With Dyslipidemia | 375,000 Collaboration ³ |
| UMA Education, Inc. dba Global Education Group | Mastering the Prior Authorization Process to Meet Patient Needs | 275,000 Collaboration ³ |

¹ Applicant names are provided by the requestor. If applicants apply as a group for a single educational activity; all applicants may not be identified above. The Company funds other educational activities (including fellowships and non-physician and patient education); all of which do not appear on this report, but appear on other reports on this site.

² "Funding Amount" is the amount that the Company funded during Q1, 2018 identified above based upon an agreement. Recipients are required to return any unused funds. Information on unused funds returned by the applicant on activities are not reported. "Funding Amount" does not include funds that may have been provided by other affiliated Sanofi Company Entities, (e.g., Sanofi Pasteur)

³ Collaboration (Shared) Funding – is the full amount of a grant funded under an agreement with Regeneron, some or all of which may be shared between the collaborating entities.

⁴ Collaboration (Shared) Funding – is the full amount of a grant funded under an agreement with Lexicon, some or all of which may be shared between the collaborating entities.

Independent Medical Education Grants

1st April 2018 – 30th June 2018

Sanofi US and its affiliate Genzyme Corporation are committed to supporting independent medical education activities in therapeutic areas in which the Company is involved, for healthcare professionals, patients, and consumers to improve patient care and health outcomes in therapeutic areas in which the Company is engaged. Sanofi US and Genzyme Corporation are part of the Sanofi Group, a global pharmaceutical company.

| Recipient Name(s) ¹ | Activity Title | Funding Amount ² |
|---|---|-----------------------------|
| Med-IQ, Inc. | Getting Social About Multiple Sclerosis: Tools for Newly Diagnosed Patients and Their Care Teams | 75,000 |
| National Association of Managed Care Physicians | Building a Better Understanding in Asthma Management: Best Practices for Treatment and Control | 57,000 |
| Excel Continuing Education | Exploring the Genetics and Management of Fabry Disease | 69,720 |
| The Trustees of Columbia University in the City of New York | The Columbia Renal Biopsy Course | 5,000 |
| Rheumatology Nurses Society Medscape Education | Updates in RA, PsA, and Biosimilars: A Pipeline View for the Clinical Nurse | 50,000 |
| University of Illinois at Chicago College of Pharmacy | Illinois Transplant Pharmacists Association Symposium | 8,000 |
| Rush University Medical Center Plexus Communications | Northern California Genitourinary Malignancy Symposium: Translating Clinical Advancements to Practical Patient Care | 10,000 |
| Medscape, LLC | Managing Multiple Myeloma: What's Next? | 116,000 |
| American Society of Transplantation | The 2018 Fellows Symposium on Transplantation | 40,000 |

¹ Applicant names are provided by the requestor. If applicants apply as a group for a single educational activity; all applicants may not be identified above. The Company funds other educational activities (including fellowships and non-physician and patient education); all of which do not appear on this report, but appear on other reports on this site.

² "Funding Amount" is the amount that the Company funded during Q2, 2018 identified above based upon an agreement. Recipients are required to return any unused funds. Information on unused funds returned by the applicant on activities are not reported. "Funding Amount" does not include funds that may have been provided by other affiliated Sanofi Company Entities, (e.g., Sanofi Pasteur)

³ Collaboration (Shared) Funding – is the full amount of a grant funded under an agreement with Regeneron, some or all of which may be shared between the collaborating entities.

⁴ Collaboration (Shared) Funding – is the full amount of a grant funded under an agreement with Lexicon, some or all of which may be shared between the collaborating entities.

Independent Medical Education Grants

1st April 2018 – 30th June 2018

| Recipient Name(s) ¹ | Activity Title | Funding Amount ² |
|--|---|-----------------------------|
| University of Louisville Research Foundation Inc. Global Academy for Medical Education Postgraduate Institute for Medicine | 11th Annual Perspectives in Rheumatic Diseases, presented by Rheumatology News, Internal Medicine News, Family Practice News | 30,000 |
| AKH Inc, Advancing Knowledge in Healthcare 47-Consultants in Medical Education University of Colorado Denver | Focusing on the Patient Voice: Utilizing Components of a Patient Coach Module Contextually within Patient-Centric CME Activities Forty-fifth annual Renal Disease and Electrolyte Disorders Course | 100,000 5,000 |
| Annenberg Center for Health Sciences at Eisenhower | Advancing Knowledge to Practice: Optimizing Severe Asthma Care in the Age of Biologics | 200,000 |
| USF Health i3 Health | Challenges and Opportunities in Metastatic Castration-Resistant Prostate Cancer: A CME/CE/CPE-Certified VA/DoD Meeting Series | 90,000 |
| Projects In Knowledge @Point of Care New Jersey Academy of Family Physicians | Multiple Sclerosis @Point of Care Ascertaining the Role of the Primary Care Clinician in the Recognition and Management of Patients With Multiple Sclerosis in the Modern Era | 75,000 5,000 |
| Med Learning Group | Pathology-Based, Targeted Therapies - Managing Moderate-to-Severe Atopic Dermatitis in Adults | 124,745 |
| Annenberg Center for Health Sciences at Eisenhower Prostate Cancer Education Council | 2018 SUNA Advanced Prostate Cancer Grant | 30,000 |
| Consortium of Multiple Sclerosis Centers Catamount Medical Education | Immune Dysfunction in Multiple Sclerosis: Modern Considerations in Treatment and Management | 75,000 |

¹ Applicant names are provided by the requestor. If applicants apply as a group for a single educational activity; all applicants may be not be identified above. The Company funds other educational activities (including fellowships and non-physician and patient education); all of which do not appear on this report, but appear on other reports on this site.

² “Funding Amount” is the amount that the Company funded during Q2, 2018 identified above based upon an agreement. Recipients are required to return any unused funds. Information on unused funds returned by the applicant on activities are not reported. “Funding Amount” does not include funds that may have been provided by other affiliated Sanofi Company Entities, (e.g., Sanofi Pasteur)

³ Collaboration (Shared) Funding – is the full amount of a grant funded under an agreement with Regeneron, some or all of which may be shared between the collaborating entities.

⁴ Collaboration (Shared) Funding – is the full amount of a grant funded under an agreement with Lexicon, some or all of which may be shared between the collaborating entities.

Independent Medical Education Grants

1st April 2018 – 30th June 2018

| Recipient Name(s) ¹ | Activity Title | Funding Amount ² |
|---|---|-----------------------------|
| Dallas County Optometric Society Fabry Support & Information Group | Eyes on Fabry Dallas County Optometric Society | 9,266 |
| Association of Reproductive Health Professionals | Snap, Crackle and Pop: Provider Education and Targeted Training to Improve the Diagnosis and Therapeutic Management of Rheumatoid Arthritis in Female Patients | 52,000 |
| AcademicCME | Improving Individualized Outcomes in Asthma with Evidence-based Treatment Strategies | 45,000 |
| Integrity Continuing Education, Inc. | 2018 Asthma State Society CME Meetings and BioDigital Human On-demand Simulation Activity - Improving Severe Asthma Control through Comprehensive Patient Assessment and Tailored Treatment Selection | 319,350 |
| UMA MLG, LLC | Targeted Therapies for the Management of Moderate-to-Severe Atopic Dermatitis in Adults - Animated Whiteboard View | 249,975 |
| Society for Investigative Dermatology | Neuro-Immunology of Skin Symposia | 75,000 |
| Penn State College of Medicine PVI, PeerView Institute for Medical Education, Inc. | PeerView Live: "Unraveling the Complex Treatment Landscape for Prostate Cancer: Guidance for Delivering Evidence-Based, Patient-Centered Care" | 60,000 |
| Medscape, LLC | Minimizing the Effects of TLS and CRS in Patients with Hematologic Malignances | 74,000 |
| Excel Continuing Education | Unraveling the Genetics and Management of MPS 1 | 55,565 |
| Hereditary Disease Foundation | Hereditary Disease Foundation's "Milton Wexler Celebration of Life" Symposium of international Huntington's disease researchers | 10,000 |

¹ Applicant names are provided by the requestor. If applicants apply as a group for a single educational activity; all applicants may not be identified above. The Company funds other educational activities (including fellowships and non-physician and patient education); all of which do not appear on this report, but appear on other reports on this site.

² "Funding Amount" is the amount that the Company funded during Q2, 2018 identified above based upon an agreement. Recipients are required to return any unused funds. Information on unused funds returned by the applicant on activities are not reported. "Funding Amount" does not include funds that may have been provided by other affiliated Sanofi Company Entities, (e.g., Sanofi Pasteur)

³ Collaboration (Shared) Funding – is the full amount of a grant funded under an agreement with Regeneron, some or all of which may be shared between the collaborating entities.

⁴ Collaboration (Shared) Funding – is the full amount of a grant funded under an agreement with Lexicon, some or all of which may be shared between the collaborating entities.

Independent Medical Education Grants

1st April 2018 – 30th June 2018

| Recipient Name(s) ¹ | Activity Title | Funding Amount ² |
|---|---|-----------------------------|
| Medscape LLC | Targeted Therapies for the Management of Severe Asthma: Surveying an Evolving Landscape | 261,500 |
| Seattle Children's Hospital | PLUGS Summit 2018: Clinical Laboratory Stewardship: Where Patient Safety and Financial Responsibility Meet | 8,000 |
| University of Cincinnati Global Academy for Medical Education Postgraduate Institute for Medicine | Skin Disease Education Foundation's 14th Women's & Pediatric Dermatology Seminar | 10,000 |
| Physicians' Education Resource, LLC (PER) | 2018 ASH Symposium: "D" is for Diagnosis: Solving the Mystery of Rare Hematologic Disorders | 250,000 |
| Boston University School of Medicine, CME | Practical Approach to Electromyography and Neuromuscular Disorders Conference | 7,500 |
| Specialty Pharma Education Center | Renal Transplantation: Overview of Advances in Clinical Understandings, Guidelines, and Treatment & Management Strategies | 49,750 |
| University of California Irvine | 8th Annual UC Irvine Neuromuscular Colloquium | 20,000 |
| Physicians' Education Resource, LLC (PER) | Oncology Briefings™: Current Perspectives on Preventing and Managing Tumor Lysis Syndrome | 50,000 |
| UMA Education Inc., dba Global Education Group MCM Education | Nursing Management of Treatment-Related Side Effects in Metastatic Prostate Cancer | 120,000 |
| UMA Education Inc., dba Global Education Group Q Synthesis, LLC | A Quality Improvement (QI) Educational Pilot on Enhancing Prostate Cancer Management in Urology Practice | 107,155 |

¹ Applicant names are provided by the requestor. If applicants apply as a group for a single educational activity; all applicants may not be identified above. The Company funds other educational activities (including fellowships and non-physician and patient education); all of which do not appear on this report, but appear on other reports on this site.

² "Funding Amount" is the amount that the Company funded during Q2, 2018 identified above based upon an agreement. Recipients are required to return any unused funds. Information on unused funds returned by the applicant on activities are not reported. "Funding Amount" does not include funds that may have been provided by other affiliated Sanofi Company Entities, (e.g., Sanofi Pasteur)

³ Collaboration (Shared) Funding – is the full amount of a grant funded under an agreement with Regeneron, some or all of which may be shared between the collaborating entities.

⁴ Collaboration (Shared) Funding – is the full amount of a grant funded under an agreement with Lexicon, some or all of which may be shared between the collaborating entities.

Independent Medical Education Grants

1st April 2018 – 30th June 2018

| Recipient Name(s) ¹ | Activity Title | Funding Amount ² |
|---|---|-----------------------------|
| Med Learning Group | Evolving Therapeutic Options for Moderate-to-Severe Asthma: A Comprehensive 3-Dimensional Study | 274,785 |
| University of Cincinnati | 2018 International Rare Lung Diseases Research Conference | 10,000 |
| Consortium of Multiple Sclerosis Centers Inc Delaware Media Group | Therapeutic Decision-Making for Disease Modification in MS: 2018 Update | 49,288 |
| Excel Continuing Education | Unraveling a Therapeutic Conundrum: ASMD Niemann Pick Disease | 106,790 |
| University of Cincinnati Advances in Cosmetic and Medical Dermatology | MauiDerm NP+PA Summer 2018 | 25,000 |
| American Thoracic Society | ATS 2018 International Conference - Selected Sessions in Asthma | 20,000 |
| Creighton University Physicians Continuing Education, Corporation | Skin of Color Seminar Series 2018 (SOCSS 2018) | 15,000 |
| UMA MLG, LLC | Treating a Chronic Autoimmune Inflammatory Disease: Targeting Pathophysiologic Cytokines in the Management of Rheumatoid Arthritis - Animated Whiteboard View | 214,500 |
| Tarrant County Organization Society Fabry Support & Information Group | Eyes on Fabry Tarrant County Optometric Society | 7,998 |
| University of Nevada, Reno School of Medicine Dermatology University LLC | 2018 Real World Dermatology for PAs and NPs | 25,000 |

¹ Applicant names are provided by the requestor. If applicants apply as a group for a single educational activity; all applicants may not be identified above. The Company funds other educational activities (including fellowships and non-physician and patient education); all of which do not appear on this report, but appear on other reports on this site.

² “Funding Amount” is the amount that the Company funded during Q2, 2018 identified above based upon an agreement. Recipients are required to return any unused funds. Information on unused funds returned by the applicant on activities are not reported. “Funding Amount” does not include funds that may have been provided by other affiliated Sanofi Company Entities, (e.g., Sanofi Pasteur)

³ Collaboration (Shared) Funding – is the full amount of a grant funded under an agreement with Regeneron, some or all of which may be shared between the collaborating entities.

⁴ Collaboration (Shared) Funding – is the full amount of a grant funded under an agreement with Lexicon, some or all of which may be shared between the collaborating entities.

Independent Medical Education Grants

1st April 2018 – 30th June 2018

| Recipient Name(s) ¹ | Activity Title | Funding Amount ² |
|---|--|-----------------------------|
| American Society of Clinical Oncology, Inc. Conquer Cancer Foundation of the American Society of Clinical Oncology | 2018 ASCO Annual Meeting Genitourinary Cancer Tracks Bundle (Prostate and Nonprostate) | 40,000 |
| Postgraduate Institute for Medicine | Clinical Care Team Exchange: The Role of New Biologics for Optimal RA Management | 425,170 |
| PRIME Education, LLC | Driving Practice Change in Systems-Based Care of Patients with Atopic Dermatitis | 344,805 |
| The Medical College of Wisconsin, Inc. Carden Jennings Publishing Co., Ltd St. Joseph's Regional Medical Center | The 23rd Annual Southwest Prostate Cancer Symposium (SPCS 23) | 5,000 |
| MS Cure Fund, Inc. | Acute Rejection of the Allograft - New Concepts and Old | 1,810 |
| | 2018 Q1 Lifestyle Management Patient Education Programs for individuals diagnosed with multiple sclerosis, and their support team. | 20,000 |
| Alaska Regional Hospital | Wheezin', Sneezin' & Itchin' in Alaska | 5,000 |
| American Academy of PAs | AAPA 2018 - Rheumatology Track | 5,000 |
| Postgraduate Institute for Medicine Impact Education, LLC | The Specialty Pharmacy Review Board™ – Examining Emerging Biologics for Difficult-to-treat or Severe Asthma | 235,000 |
| National Association of Managed Care Physicians | Individualizing Therapy in the Management of Relapsing Multiple Sclerosis: Expert Switching and Sequencing Strategies | 45,000 |
| Consortium of Multiple Sclerosis Centers Inc International Organization of MS Nurses | Nursing Care in Multiple Sclerosis: Evidence-Based Practice | 75,000 |

¹ Applicant names are provided by the requestor. If applicants apply as a group for a single educational activity; all applicants may not be identified above. The Company funds other educational activities (including fellowships and non-physician and patient education); all of which do not appear on this report, but appear on other reports on this site.

² “Funding Amount” is the amount that the Company funded during Q2, 2018 identified above based upon an agreement. Recipients are required to return any unused funds. Information on unused funds returned by the applicant on activities are not reported. “Funding Amount” does not include funds that may have been provided by other affiliated Sanofi Company Entities, (e.g., Sanofi Pasteur)

³ Collaboration (Shared) Funding – is the full amount of a grant funded under an agreement with Regeneron, some or all of which may be shared between the collaborating entities.

⁴ Collaboration (Shared) Funding – is the full amount of a grant funded under an agreement with Lexicon, some or all of which may be shared between the collaborating entities.

Independent Medical Education Grants

1st April 2018 – 30th June 2018

| Recipient Name(s) ¹ | Activity Title | Funding Amount ² |
|---|--|---------------------------------------|
| The Annenberg Center for Health Sciences at Eisenhower prIME Oncology, LLC | How I Treat Advanced Prostate Cancer: Making Sense of the Ever-Increasing Options | 100,000 |
| Elsevier Office of COntinuing Medical Education Integritas Communications | Clinical Issues in Atopic Dermatitis: Discussions and Debates on Managing Moderate-to-Severe Disease | 784,642 |
| Horizon CME, Inc. | How to Select and Start Insulin in Patients with Type 2 Diabetes: A Hands-on Workshop | 59,925 |
| National Association For Continuing Education | Getting Comfortable with Insulin: New Approaches to Getting Patients Safely to Target | 355,396 |
| Medscape LLC | Improving Use of Basal Insulin for Better Diabetes Outcomes | 800,000 |
| Pri-Med Institute, LLC (d/b/a pmiCME) | The Southern Diabetes Initiative: Individualizing Care in the 21st Century | 400,000 |
| Elsevier Office of Continuing Medical Education | Emerging Strategies for Achieving Glycemic Control in Adults with Type 1 Diabetes | 179,950 Collaboration ⁴ |
| The France Foundation | When Insulin Isn't Enough: Exploring Dual SGLT1 and SGLT2 Inhibition in T1DM | 153,900 Collaboration ⁴ |
| NACCME, LLC. | Integrating Emerging Evidence in Adjunctive Therapies Into Team-Based Management Strategies in Type 1 Diabetes | 432,535 Collaboration ⁴ |
| Med-IQ, LLC | Evolving Evidence in Type 1 Diabetes Management: Evaluating the Role of SGLT Inhibition | 238,281 Collaboration ⁴ |

¹ Applicant names are provided by the requestor. If applicants apply as a group for a single educational activity; all applicants may not be identified above. The Company funds other educational activities (including fellowships and non-physician and patient education); all of which do not appear on this report, but appear on other reports on this site.

² "Funding Amount" is the amount that the Company funded during Q2, 2018 identified above based upon an agreement. Recipients are required to return any unused funds. Information on unused funds returned by the applicant on activities are not reported. "Funding Amount" does not include funds that may have been provided by other affiliated Sanofi Company Entities, (e.g., Sanofi Pasteur)

³ Collaboration (Shared) Funding – is the full amount of a grant funded under an agreement with Regeneron, some or all of which may be shared between the collaborating entities.

⁴ Collaboration (Shared) Funding – is the full amount of a grant funded under an agreement with Lexicon, some or all of which may be shared between the collaborating entities.

Independent Medical Education Grants

1st April 2018 – 30th June 2018

| Recipient Name(s) ¹ | Activity Title | Funding Amount ² |
|---|--|---------------------------------------|
| UMA Education Inc., dba Global Education Group | Type 1 Diabetes: New and Emerging Therapeutic Strategies to Address Unmet Needs | 511,628 Collaboration ⁴ |
| Haymarket Medical Education | GLP-1 Receptor Agonists: Injecting More Confidence in Achieving Glycemic Control for Patients With T2DM The my CME Town Wall: A Live Clinical Forum for Multiple Viewpoints on a Virtual Stage | 49,950 |
| Medscape LLC | Novel Treatments for T1D | 499,000 Collaboration ⁴ |
| Med-IQ, Inc. | Initiating Insulin in Patients Who Fear Needles: Using Evolving Basal Insulins to Improve Adoption | 297,385 |
| National Association of Managed Care Physicians | The Role of PCSK9 Inhibitors in Lowering LDL-C in Patients with Dyslipidemia: What Managed Care Needs to Know | 95,000 Collaboration ³ |
| Allina Health Minneapolis Heart Institute Foundation | PCSK9 Inhibitors – Science, Selection and Access | 5,000 Collaboration ³ |
| Medscape LLC | PCSK9 Inhibitors and Cardiovascular Outcomes: ACC 2018 Data You Cannot Afford to Miss | 237,125 Collaboration ³ |
| Postgraduate Institute for Medicine CMEducation Resources, LLC | The Landmark trial-based evidence and rationale for PCSK9 inhibition to prevent and treat Atherosclerotic Cardiovascular Disease (ASCVD) | 398,000 Collaboration ³ |
| National Lipid Association Horizon CME, Inc. | PCSK9 Inhibitors in Practice: Real-World Challenges and Solutions | 261,335 Collaboration ³ |

¹ Applicant names are provided by the requestor. If applicants apply as a group for a single educational activity; all applicants may not be identified above. The Company funds other educational activities (including fellowships and non-physician and patient education); all of which do not appear on this report, but appear on other reports on this site.

² “Funding Amount” is the amount that the Company funded during Q2, 2018 identified above based upon an agreement. Recipients are required to return any unused funds. Information on unused funds returned by the applicant on activities are not reported. “Funding Amount” does not include funds that may have been provided by other affiliated Sanofi Company Entities, (e.g., Sanofi Pasteur)

³ Collaboration (Shared) Funding – is the full amount of a grant funded under an agreement with Regeneron, some or all of which may be shared between the collaborating entities.

⁴ Collaboration (Shared) Funding – is the full amount of a grant funded under an agreement with Lexicon, some or all of which may be shared between the collaborating entities.

Independent Medical Education Grants

1st April 2018 – 30th June 2018

| Recipient Name(s) ¹ | Activity Title | Funding Amount ² |
|---|---|---------------------------------------|
| National Lipid Association | The New Era of Preventive Cardiology: Applying PCSK9 Inhibitor Therapeutics to Prevent Heart Attack and Stroke | 153,000 Collaboration ³ |
| Postgraduate Institute for Medicine CMEducation Resources, LLC | New Evidence-Based, Therapeutic Strategies for applying CV outcome and trial-based evidence for PCSK9 inhibition to the front lines of CAD Prevention and Treatment | 397,000 Collaboration ³ |
| Med Learning Group | A Virtual Reality Tour of Nonstatin LDL-C-lowering Agents that Decrease Cardiovascular Risk for Patients with Persistent Hypercholesterolemia | 573,725 Collaboration ³ |
| Potomac Center for Medical Education | Role of Interventional Cardiologists in Secondary Prevention of Myocardial Infarction: Redefining Clinical Practice | 198,450 Collaboration ³ |
| North American Center for Continuing Medical Education, LLC | Cardiology Grand Rounds: Overcoming Access Barriers and Practice Challenges to PCSK9 Inhibitor Implementation | 476,838 Collaboration ³ |
| PRIME Education, LLC | Applying the Latest Cardiovascular Outcomes Trial Evidence to PCSK9 Inhibitor Decision-Making in Lipid Management | 146,740 Collaboration ³ |
| Pri-Med Institute, LLC (d/b/a pmiCME) Horizon CME, Inc. | Translating Evidence to Practice: Improving Outcomes in Patients with ASCVD with PCSK9 Inhibitors | 575,150 Collaboration ³ |
| Med Learning Group | A Virtual Reality In Practice View: Maximizing Clinical Benefit Through Optimal LDL-C Reductions in Patients With Atherosclerotic Disease | 174,400 Collaboration ³ |

¹ Applicant names are provided by the requestor. If applicants apply as a group for a single educational activity; all applicants may be not be identified above. The Company funds other educational activities (including fellowships and non-physician and patient education); all of which do not appear on this report, but appear on other reports on this site.

² “Funding Amount” is the amount that the Company funded during Q2, 2018 identified above based upon an agreement. Recipients are required to return any unused funds. Information on unused funds returned by the applicant on activities are not reported. “Funding Amount” does not include funds that may have been provided by other affiliated Sanofi Company Entities, (e.g., Sanofi Pasteur)

³ Collaboration (Shared) Funding – is the full amount of a grant funded under an agreement with Regeneron, some or all of which may be shared between the collaborating entities.

⁴ Collaboration (Shared) Funding – is the full amount of a grant funded under an agreement with Lexicon, some or all of which may be shared between the collaborating entities.

Independent Medical Education Grants

1st April 2018 – 30th June 2018

| Recipient Name(s) ¹ | Activity Title | Funding Amount ² |
|---|--|---------------------------------------|
| Physicians' Education Resource | 2018 New York Multidisciplinary Cardio-Endo-Renal Collaborative: Access to PCSK9i: Updates on Guidelines, Emerging Cardiovascular Benefits and Overcoming Barriers to Access | 35,000 Collaboration ³ |
| PRIME Education, LLC | Integrating Evidence from the Latest Cardiovascular Outcomes Data into Managed Care Decision-Making in Lipid Management | 459,799 Collaboration ³ |
| The Academy for Continued Healthcare Learning | Improving Outcomes and Expanding Opportunities for the Treatment of Hyperlipidemia | 180,420 Collaboration ³ |

¹ Applicant names are provided by the requestor. If applicants apply as a group for a single educational activity; all applicants may not be identified above. The Company funds other educational activities (including fellowships and non-physician and patient education); all of which do not appear on this report, but appear on other reports on this site.

² "Funding Amount" is the amount that the Company funded during Q2, 2018 identified above based upon an agreement. Recipients are required to return any unused funds. Information on unused funds returned by the applicant on activities are not reported. "Funding Amount" does not include funds that may have been provided by other affiliated Sanofi Company Entities, (e.g., Sanofi Pasteur)

³ Collaboration (Shared) Funding – is the full amount of a grant funded under an agreement with Regeneron, some or all of which may be shared between the collaborating entities.

⁴ Collaboration (Shared) Funding – is the full amount of a grant funded under an agreement with Lexicon, some or all of which may be shared between the collaborating entities.

Independent Medical Education Grants

1st July 2018 – 30th Sept 2018

Sanofi US and its affiliate Genzyme Corporation are committed to supporting independent medical education activities in therapeutic areas in which the Company is involved, for healthcare professionals, patients, and consumers to improve patient care and health outcomes in therapeutic areas in which the Company is engaged. Sanofi US and Genzyme Corporation are part of the Sanofi Group, a global pharmaceutical company.

| Recipient Name(s) ¹ | Activity Title | Funding Amount ² |
|---|--|-----------------------------|
| Integrity Continuing Education, Inc. | Advancing Diagnosis and Management of Atopic Dermatitis in Children and Adolescents - Practitioner's Edge State Society Meeting Series, CaseScribe On-demand Activity, and Mobile Coach Platform | 318,450 |
| Penn State College of Medicine PVI, PeerView Institute for Medical Education, Inc. | PeerView inSession, "An Expert Analysis of New Data for Uncontrolled Persistent Asthma Treatments: Clinical Updates From Paris") | 76,740 |
| Medscape LLC | Advances in Severe Asthma Management: Conference Highlights and Perspectives | 219,500 |
| PRIME Education, LLC | 4th Annual Regional Meetings for Providers in Federal and Public Healthcare Sectors: Interprofessional Education on Psoriatic Diseases, Atopic Dermatitis, and Rheumatoid Arthritis | 188,000 |
| Medscape LLC | Guide to Atopic Dermatitis: Clinical Pearls for Dermatologists and Allergists | 198,400 |
| MediCom Worldwide, Inc. | 2018 ASH Meeting on Hematologic Malignancies: The Art and Science of Relapsed/ Refractory Multiple Myeloma: A Practical Guide to Complex Therapeutic Choices | 25,000 |
| Medscape LLC | The Pediatrician's Role in Atopic Dermatitis | 458,225 |

¹ Applicant names are provided by the requestor. If applicants apply as a group for a single educational activity; all applicants may not be identified above. The Company funds other educational activities (including fellowships and non-physician and patient education); all of which do not appear on this report, but appear on other reports on this site.

² "Funding Amount" is the amount that the Company funded during Q3, 2018 identified above based upon an agreement. Recipients are required to return any unused funds. Information on unused funds returned by the applicant on activities are not reported. "Funding Amount" does not include funds that may have been provided by other affiliated Sanofi Company Entities, (e.g., Sanofi Pasteur)

³ Collaboration (Shared) Funding – is the full amount of a grant funded under an agreement with Regeneron, some or all of which may be shared between the collaborating entities.

⁴ Collaboration (Shared) Funding – is the full amount of a grant funded under an agreement with Lexicon, some or all of which may be shared between the collaborating entities.

Independent Medical Education Grants

1st July 2018 – 30th Sept 2018

| Recipient Name(s) ¹ | Activity Title | Funding Amount ² |
|---|--|-----------------------------|
| Integrity Continuing Education, Inc. | Strategies to Provide Individualized Treatment in Moderate-to-Severe Atopic Dermatitis - Practitioner's Edge State Society Meeting Series and Publication in Action On-demand Activity | 360,900 |
| Regents of the University of California | Frontiers in Autosomal Dominant Polycystic Kidney Disease (ADPKD) | 10,000 |
| National Association of Managed Care Physicians | Optimizing Clinical and Economic Outcomes in the Management of Moderate to Severe Atopic Dermatitis: Taking a Closer Look at the Role of Biologic Therapies | 57,000 |
| National Jewish Health Catamount Medical Education, LLC | What is Multiple Myeloma? A Game-Based Learning Experience on Novel Treatment Strategies for Multiple Myeloma | 75,000 |
| Medical Learning Institute, Inc. PVI, PeerView Institute for Medical Education, Inc. | PeerView inVision, Expert Insights on Available and Emerging Therapies for the Management Pompe Disease | 122,250 |
| ScientiaCME LLC | Treatment strategies in Fabry disease | 17,800 |
| UMA MLG, LLC | Utilizing the Molecular/Physiologic Phenotype to Direct Asthma Therapy: A Comprehensive Infographic View | 289,400 |
| CME Outfitters, LLC | Atopic Dermatitis: You Can't Improve What You Don't Measure | 279,850 |
| The University of Kansas Medical Center - Continuing Medical Education | The Changing Landscape of Neuromuscular Disease: The Future is Here | 40,000 |
| Oakstone Publishing, LLC. | Getting Under the Skin with Targeted Therapy to Improve Atopic Dermatitis Management | 170,000 |

¹ Applicant names are provided by the requestor. If applicants apply as a group for a single educational activity; all applicants may not be identified above. The Company funds other educational activities (including fellowships and non-physician and patient education); all of which do not appear on this report, but appear on other reports on this site.

² "Funding Amount" is the amount that the Company funded during Q3, 2018 identified above based upon an agreement. Recipients are required to return any unused funds. Information on unused funds returned by the applicant on activities are not reported. "Funding Amount" does not include funds that may have been provided by other affiliated Sanofi Company Entities, (e.g., Sanofi Pasteur)

³ Collaboration (Shared) Funding – is the full amount of a grant funded under an agreement with Regeneron, some or all of which may be shared between the collaborating entities.

⁴ Collaboration (Shared) Funding – is the full amount of a grant funded under an agreement with Lexicon, some or all of which may be shared between the collaborating entities.

Independent Medical Education Grants

1st July 2018 – 30th Sept 2018

| Recipient Name(s) ¹ | Activity Title | Funding Amount ² |
|--|---|-----------------------------|
| University of Cincinnati Global Academy for Medical Education Postgraduate Institute For Medicine | 14th Annual Coastal Dermatology Symposium | 10,000 |
| MediCom Worldwide, Inc. | 2018 Meeting Highlights of the 4th International Conference on Multiple Myeloma | 12,500 |
| National Comprehensive Cancer Network | NCCN 13th Annual Congress: Hematologic Malignancies™ | 25,000 |
| Boston Children's Hospital/Division of Genetics and Genomics | Metabolism Conference Series | 10,000 |
| Postgraduate Institute for Medicine PlatformQ Health Education, LLC Asthma and Allergy Foundation of America | Incorporating New Agents into the Management of Atopic Dermatitis | 375,400 |
| Purdue University MCM Education | Improving the Management of Severe Asthma in Patients with Type 2 Inflammation | 125,000 |
| Cedars-Sinai | 8th Annual Symposium on Lysosomal Storage Disorders | 20,000 |
| AMERICAN UROLOGICAL ASSOCIATION | Use of Novel Hormonal Agents and Systemic Therapy in Advanced Prostate Cancer | 50,000 |
| Med Learning Group | In Pursuit of Clinical Remission: Optimizing the Pharmacologic Management of Rheumatoid Arthritis | 249,850 |
| Physicians' Education Resource, LLC (PER) | Cancer Summaries and Commentaries™: Report from San Diego on Advancements in Multiple Myeloma | 50,000 |

¹ Applicant names are provided by the requestor. If applicants apply as a group for a single educational activity; all applicants may not be identified above. The Company funds other educational activities (including fellowships and non-physician and patient education); all of which do not appear on this report, but appear on other reports on this site.

² "Funding Amount" is the amount that the Company funded during Q3, 2018 identified above based upon an agreement. Recipients are required to return any unused funds. Information on unused funds returned by the applicant on activities are not reported. "Funding Amount" does not include funds that may have been provided by other affiliated Sanofi Company Entities, (e.g., Sanofi Pasteur)

³ Collaboration (Shared) Funding – is the full amount of a grant funded under an agreement with Regeneron, some or all of which may be shared between the collaborating entities.

⁴ Collaboration (Shared) Funding – is the full amount of a grant funded under an agreement with Lexicon, some or all of which may be shared between the collaborating entities.

Independent Medical Education Grants

1st July 2018 – 30th Sept 2018

| Recipient Name(s) ¹ | Activity Title | Funding Amount ² |
|--|--|-----------------------------|
| Physicians' Education Resource, LLC (PER) | 2019 ASCO GU Symposium: Prostate Cancer Tumor Board: Integration of Recent Data Sets Across Lines of Care | 100,000 |
| University of Pittsburgh | 2018 Pittsburgh International Lung Conference - Pulmonary Medicine: Basic Biology and Novel Therapies | 10,000 |
| American College of Chest Phys | Update on Moderate-to-Severe Asthma for Specialists: Conference Coverage from CHEST 2018 | 500,000 |
| American Academy of Physician Assistants in Allergy, Asthma & Immunology | 10th Annual Allergy, Asthma & ENT CME Conference | 5,000 |
| Oakstone Publishing, LLC. Answers in CME Inc. | Strategies for Success in Rheumatoid Arthritis Treatment: Integrating the Patient Voice | 170,000 |
| American College of Allergy, Asthma & Immunology | An interactive Case Discussion of a Young Adult with Severe Atopic Dermatitis: Insights from the Expert | 40,000 |
| UT Southwestern Medical Center Medical Logix, LLC | Treatment Approaches and Therapies for Highly Active Multiple Sclerosis: Implementing Updated MS Guidelines | 83,350 |
| National Association of Managed Care Physicians | Implementing Personalized Therapeutic Strategies of Switching and Sequencing to Improve Patient Outcomes in the Management of Multiple Sclerosis | 45,000 |
| Projects In Knowledge | MedImage Cases: Multiple Sclerosis | 75,000 |

¹ Applicant names are provided by the requestor. If applicants apply as a group for a single educational activity; all applicants may not be identified above. The Company funds other educational activities (including fellowships and non-physician and patient education); all of which do not appear on this report, but appear on other reports on this site.

² "Funding Amount" is the amount that the Company funded during Q3, 2018 identified above based upon an agreement. Recipients are required to return any unused funds. Information on unused funds returned by the applicant on activities are not reported. "Funding Amount" does not include funds that may have been provided by other affiliated Sanofi Company Entities, (e.g., Sanofi Pasteur)

³ Collaboration (Shared) Funding – is the full amount of a grant funded under an agreement with Regeneron, some or all of which may be shared between the collaborating entities.

⁴ Collaboration (Shared) Funding – is the full amount of a grant funded under an agreement with Lexicon, some or all of which may be shared between the collaborating entities.

Independent Medical Education Grants

1st July 2018 – 30th Sept 2018

| Recipient Name(s) ¹ | Activity Title | Funding Amount ² |
|---|---|-----------------------------|
| American Society of Transplant Surgeons | 12 Annual Surgical Fellows Symposium | 110,000 |
| Medscape LLC | Management Challenges in Rheumatoid Arthritis: A Virtual Simulation Approach | 250,000 |
| Michael J. Fox Foundation For Parkinson's Research | MDS-PAS Movement Disorders School for Neurology Residents | 20,000 |
| Society for Inherited Metabolic Disorders | 2018 North American Metabolic Academy | 25,000 |
| Duke University | 2018 Duke Solid Organ Transplant Summit | 15,000 |
| American Society of Nephrology University of Minnesota | Fabry Disease for the Nephrologist: Present and Future | 125,000 |
| American College of Allergy, Asthma & Immunology | Thursday Morning Session: Biologic Therapies in Your Practice | 77,875 |
| Physicians' Education Resource® (PER®) | Advances in™ Therapies for Patients with Multiple Myeloma: More Options... More Decisions... Better Outcomes | 60,000 |
| Oakstone Publishing, LLC. Answers in CME Inc. | Making the Case for Stepping Up Therapy for Atopic Dermatitis | 185,000 |
| Oakstone Publishing, LLC. Answers in CME Inc. | Assessing the Impact of AD: Physical and Beyond | 170,000 |
| Postgraduate Institute for Medicine Enquiring Minds, LLC | Recognizing and Managing Suboptimal Therapeutic Response in MS: Expert Guidance on Challenging Cases | 35,000 |
| JPatible | JPatible Jewish Genetic Screening and Couple Compatibility Matching Program | 77,500 |

¹ Applicant names are provided by the requestor. If applicants apply as a group for a single educational activity; all applicants may not be identified above. The Company funds other educational activities (including fellowships and non-physician and patient education); all of which do not appear on this report, but appear on other reports on this site.

² "Funding Amount" is the amount that the Company funded during Q3, 2018 identified above based upon an agreement. Recipients are required to return any unused funds. Information on unused funds returned by the applicant on activities are not reported. "Funding Amount" does not include funds that may have been provided by other affiliated Sanofi Company Entities, (e.g., Sanofi Pasteur)

³ Collaboration (Shared) Funding – is the full amount of a grant funded under an agreement with Regeneron, some or all of which may be shared between the collaborating entities.

⁴ Collaboration (Shared) Funding – is the full amount of a grant funded under an agreement with Lexicon, some or all of which may be shared between the collaborating entities.

Independent Medical Education Grants

1st July 2018 – 30th Sept 2018

| Recipient Name(s) ¹ | Activity Title | Funding Amount ² |
|---|---|-----------------------------|
| Illinois Academy of Physician Assistants | Multiple Sclerosis | 6,500 |
| American Society for Reconstructive Transplantation | Vascularized Composite Tissue Allografts: What it Takes to Succeed | 30,152 |
| Massachusetts Association of Physician Assistants | “Multiple Sclerosis” | 4,800 |
| i3 Health | Castration-Resistant Prostate Cancer: Implementing New Data and Evolving Standards | 86,975 |
| Mayo Clinic College of Medicine and Science SPARGO Inc. on behalf of the International Myeloma Society | International Myeloma Society Educational Workshop | 50,000 |
| UCSF Office of CME | UCSF TRANSPLANT 2018: Pioneering Advances in Transplantation | 5,000 |
| The University of Texas MD Anderson Cancer Center ASiM CE, LLC | Emerging Therapeutic Strategies for Relapsed and Refractory Multiple Myeloma: Highlights from ASH 2018 | 50,000 |
| Regents of the University of Colorado American Thyroid Association | 88th Annual Meeting of the American Thyroid Association and the 2018 Annual Ridgway Trainee Conference | 75,000 |
| National Association For Continuing Education | Matching Pathogenesis and Treatment in Atopic Dermatitis: The Evolving Science | 92,800 |
| The Medical College of Wisconsin PVI, PeerView Institute for Medical Education | PeerView Live at the 2019 TCT Meetings - 'Innovative Therapies and Concepts in Transplant-Eligible Patients With Myeloma: Advancing Toward More Effective Care Across Treatment Settings' | 119,477 |
| Physicians' Education Resource, LLC (PER) | Medical Crossfire®: How Can We Best Leverage the Use of MRD to Optimize Outcomes in the Management of Hematologic Malignances? | 50,000 |

¹ Applicant names are provided by the requestor. If applicants apply as a group for a single educational activity; all applicants may not be identified above. The Company funds other educational activities (including fellowships and non-physician and patient education); all of which do not appear on this report, but appear on other reports on this site.

² “Funding Amount” is the amount that the Company funded during Q3, 2018 identified above based upon an agreement. Recipients are required to return any unused funds. Information on unused funds returned by the applicant on activities are not reported. “Funding Amount” does not include funds that may have been provided by other affiliated Sanofi Company Entities, (e.g., Sanofi Pasteur)

³ Collaboration (Shared) Funding – is the full amount of a grant funded under an agreement with Regeneron, some or all of which may be shared between the collaborating entities.

⁴ Collaboration (Shared) Funding – is the full amount of a grant funded under an agreement with Lexicon, some or all of which may be shared between the collaborating entities.

Independent Medical Education Grants

1st July 2018 – 30th Sept 2018

| Recipient Name(s) ¹ | Activity Title | Funding Amount ² |
|---|---|-----------------------------|
| Postgraduate Healthcare Education, LLC Postgraduate Institute for Medicine (PIM) | Identification and Management of Atopic Dermatitis: Applying Advances to Improve Outcomes A PHE/Power-Pak Initiative Program 2: Treatment and Emerging Therapies in Moderate-to-Severe Atopic Dermatitis | 154,500 |
| Physicians' Education Resource, LLC (PER) The Medical College of Wisconsin, Inc | Optimizing Outcomes Through Stem Cell Mobilization: Applying Evidence to Patients with Multiple Myeloma and Non-Hodgkin's Lymphoma | 300,000 |
| Continuing Education Alliance | PCE Directed Learning eCourse plus eMinders and Reinforcements: Changing Pathways in Moderate to Severe Atopic Dermatitis | 148,275 |
| American Academy of CME, Inc. | Reversing the Trend in Living Kidney Donation: Improving Risk Assessment and Increasing Access | 122,875 |
| Postgraduate Institute for Medicine | Applying Precision Medicine in Severe and Difficult-to-Treat Asthma. | 322,100 |
| Penn State College of Medicine Research To Practice | Consensus or Controversy? Clinical Investigators Provide Perspectives on the Current and Future Management of Patients with Prostate Cancer— An Independent Satellite Symposium (ISS) Held as a Premium Ancillary Educational Event During the 2019 Genitourinary Cancers Symposium | 95,000 |
| Excel Continuing Education | Newborn Screening for Rare Disorders: Focusing on Pompe Disease and Gaucher Disease | 77,575 |
| Excel Continuing Education | "Multiple Sclerosis: Treating and Managing Symptoms" | 5,000 |
| Medical Learning Institute, Inc. PVI, PeerView Institute for Medical Education, Inc. | PeerView inSession, Taking Stock of Late-Breaking Data on Disease-Modifying Therapies for the Treatment of Multiple Sclerosis: What Are the Key Learnings from Berlin? | 50,000 |

¹ Applicant names are provided by the requestor. If applicants apply as a group for a single educational activity; all applicants may not be identified above. The Company funds other educational activities (including fellowships and non-physician and patient education); all of which do not appear on this report, but appear on other reports on this site.

² "Funding Amount" is the amount that the Company funded during Q3, 2018 identified above based upon an agreement. Recipients are required to return any unused funds. Information on unused funds returned by the applicant on activities are not reported. "Funding Amount" does not include funds that may have been provided by other affiliated Sanofi Company Entities, (e.g., Sanofi Pasteur)

³ Collaboration (Shared) Funding – is the full amount of a grant funded under an agreement with Regeneron, some or all of which may be shared between the collaborating entities.

⁴ Collaboration (Shared) Funding – is the full amount of a grant funded under an agreement with Lexicon, some or all of which may be shared between the collaborating entities.

Independent Medical Education Grants

1st July 2018 – 30th Sept 2018

| Recipient Name(s) ¹ | Activity Title | Funding Amount ² |
|---|--|--------------------------------------|
| UMA MLG, LLC | A 3D View: Moderate-to-Severe Atopic Dermatitis in the Pediatric Population: Long-term Treatment and Managed Care Issues | 425,000 |
| Postgraduate Institute for Medicine RMEI | A Learning Pathway for Clinicians in Multiple Sclerosis: Practical Strategies for Early Diagnosis and Informed Management | 50,000 |
| Postgraduate Institute for Medical Education Global Academy for Medical Education | Atopic Dermatitis: A Specialist Perspective on Diagnosis and Management Across the Age Spectrum | 300,000 |
| American Academy of CME, Inc | Crucial Conversations in Rare & Orphan Disease: Challenges of Diagnosing Rare Diseases: A Focus on Gaucher Disease | 36,000 |
| Consortium of Multiple Sclerosis Centers PlatformQ Health Education, LLC | Improving Multiple Sclerosis Care: Integrating Patient-Provider Perspectives | 60,000 |
| Postgraduate Healthcare Education Spire Learning Integrity Continuing Education, Inc. | The Pharmacist's Role in Managing Disease-Modifying Therapies in Adults With Multiple Sclerosis | 30,000 |
| | Improving Diagnosis and Treatment of Atopic Dermatitis through Collaborative Primary & Specialist Care - Practitioner's Edge State Society Meeting Series and CME Audit and Feedback Practice Assessment | 299,800 |
| Regents of the University of Colorado | Practical Ways to Achieve Targets in Diabetes Care (ATDC) | 25,000 Collaboration ⁴ |
| Regents of the University of Colorado | Practical Ways to Achieve Targets in Diabetes Care (ATDC) | 50,000 |
| Regents of the University of Colorado | Practical Ways to Achieve Targets in Diabetes Care (ATDC) | 75,000 |
| Horizon CME, Inc. | Can We Do It Better: Improving Outcomes in the Management of Patients with Atrial Fibrillation | 165,100 |

¹ Applicant names are provided by the requestor. If applicants apply as a group for a single educational activity; all applicants may not be identified above. The Company funds other educational activities (including fellowships and non-physician and patient education); all of which do not appear on this report, but appear on other reports on this site.

² "Funding Amount" is the amount that the Company funded during Q3, 2018 identified above based upon an agreement. Recipients are required to return any unused funds. Information on unused funds returned by the applicant on activities are not reported. "Funding Amount" does not include funds that may have been provided by other affiliated Sanofi Company Entities, (e.g., Sanofi Pasteur)

³ Collaboration (Shared) Funding – is the full amount of a grant funded under an agreement with Regeneron, some or all of which may be shared between the collaborating entities.

⁴ Collaboration (Shared) Funding – is the full amount of a grant funded under an agreement with Lexicon, some or all of which may be shared between the collaborating entities.

Independent Medical Education Grants

1st July 2018 – 30th Sept 2018

| Recipient Name(s) ¹ | Activity Title | Funding Amount ² |
|--|--|---------------------------------------|
| Integrity Continuing Education, Inc. | 2019 AAFP State Society CME Meetings, Hands-on Workshop And BioDigital Human On-demand Simulation Activity: Overcoming Barriers to Initiating or Intensifying Insulin Therapy: Best Practices for the Family Physician | 160,000 |
| NACCME, LLC. | Cardiology Grand Rounds: Diagnostic and Pharmacotherapeutic Strategies for the Individualized Management of Atrial Fibrillation | 221,710 |
| University of Cincinnati | New Developments in Type 2 Diabetes Treatment to Decrease the Risk of Hypoglycemia | 275,000 |
| Medscape LLC | Lipid Clinic Considerations: What Would You Do? A Live Patient Simulation | 447,220 Collaboration ³ |
| PRIME Education, LLC | Patients, Payers, Providers Opine: When to Treat with PCSK9s | 445,879 Collaboration ³ |
| Boston University School of Medicine Practicing Clinicians Exchange (PCE) | 2018 PCE Series 3 Live and Enduring Home Study with Eminders and Reinforcement Activities - Evolution of Dyslipidemia Management: The Expanding Role of PCSK9 Inhibitors | 225,000 Collaboration ³ |
| Association of Black Cardiologists, Inc. | Managing Lipids and Cardiovascular Risk: Using the Data to Optimize Care | 250,000 Collaboration ³ |
| Pharmacy Times Continuing Education | An American Journal of Managed Care (AJMC) Payor and Specialty Pharmacy Forum: Discussing Clinical Updates and Outcomes Data for PCSK9 Inhibitors | 51,850 Collaboration ³ |

¹ Applicant names are provided by the requestor. If applicants apply as a group for a single educational activity; all applicants may not be identified above. The Company funds other educational activities (including fellowships and non-physician and patient education); all of which do not appear on this report, but appear on other reports on this site.

² “Funding Amount” is the amount that the Company funded during Q3, 2018 identified above based upon an agreement. Recipients are required to return any unused funds. Information on unused funds returned by the applicant on activities are not reported. “Funding Amount” does not include funds that may have been provided by other affiliated Sanofi Company Entities, (e.g., Sanofi Pasteur)

³ Collaboration (Shared) Funding – is the full amount of a grant funded under an agreement with Regeneron, some or all of which may be shared between the collaborating entities.

⁴ Collaboration (Shared) Funding – is the full amount of a grant funded under an agreement with Lexicon, some or all of which may be shared between the collaborating entities.

Independent Medical Education Grants

1st July 2018 – 30th Sept 2018

| Recipient Name(s) ¹ | Activity Title | Funding Amount ² |
|--|---|---------------------------------------|
| Med-IQ, Inc. | Exploring Treatment Intensification in Type 2 Diabetes: Focus on the Provider-Patient Collaborative | 250,050 |
| UMA MLG, LLC | An In Practice View: Moving Beyond Statins To Decrease Cardiovascular Events in Patients With Atherosclerotic Disease | 178,150 Collaboration ³ |
| Oakstone Publishing, LLC. Answers in CME Inc. | Putting Cardiovascular Outcomes Data Into Context: How Will the Latest Information on PCSK9 Inhibitors Change Practice? | 170,000 Collaboration ³ |

¹ Applicant names are provided by the requestor. If applicants apply as a group for a single educational activity; all applicants may not be identified above. The Company funds other educational activities (including fellowships and non-physician and patient education); all of which do not appear on this report, but appear on other reports on this site.

² “Funding Amount” is the amount that the Company funded during Q3, 2018 identified above based upon an agreement. Recipients are required to return any unused funds. Information on unused funds returned by the applicant on activities are not reported. “Funding Amount” does not include funds that may have been provided by other affiliated Sanofi Company Entities, (e.g., Sanofi Pasteur)

³ Collaboration (Shared) Funding – is the full amount of a grant funded under an agreement with Regeneron, some or all of which may be shared between the collaborating entities.

⁴ Collaboration (Shared) Funding – is the full amount of a grant funded under an agreement with Lexicon, some or all of which may be shared between the collaborating entities.

Independent Medical Education Grants

1st Oct 2018 – 31ST Dec 2018

Sanofi US and its affiliate Genzyme Corporation are committed to supporting independent medical education activities in therapeutic areas in which the Company is involved, for healthcare professionals, patients, and consumers to improve patient care and health outcomes in therapeutic areas in which the Company is engaged. Sanofi US and Genzyme Corporation are part of the Sanofi Group, a global pharmaceutical company.

| Recipient Name(s) ¹ | Activity Title | Funding Amount ² |
|--|--|-----------------------------|
| NACCME, LLC. Horizon CME | Clinical and Cost Considerations for Value-Based Multiple Sclerosis Care | 74,875 |
| AKH, Inc Catalyst Medical Education, LLC. | Improving Care for Patients with Pompe Disease: A Look at Emerging Therapies and Multidisciplinary Management Strategies | 239,740 |
| Medical Education Resources Impact Education, LLC | Managing Clinical and Cost Outcomes in Multiple Sclerosis: Expert Insights | 75,000 |
| i3 Health | Current Trends in the Management of Castration-Resistant Prostate Cancer | 47,530 |
| Oakstone Publishing, LLC. Answers in CME Inc. | A Breath of Fresh Air: Exploring Pathophysiology and Novel Therapeutic Options to Improve Outcomes in Moderate-to-Severe Asthma | 340,000 |
| ANA NY, ISONG | 2018 ISONG Congress - Building Connections to Genomic Health | 2,500 |
| Affinity CE/PESG LDRTC | Genetic Rare and Immune Disorders Symposium-GRIDS 2018 GRIDS 2018 title: Late and Attenuated Presentations of Lysosomal Storage Disorders | 50,000 |

¹ Applicant names are provided by the requestor. If applicants apply as a group for a single educational activity; all applicants may not be identified above. The Company funds other educational activities (including fellowships and non-physician and patient education); all of which do not appear on this report, but appear on other reports on this site.

² “Funding Amount” is the amount that the Company funded during Q4, 2018 identified above based upon an agreement. Recipients are required to return any unused funds. Information on unused funds returned by the applicant on activities are not reported. “Funding Amount” does not include funds that may have been provided by other affiliated Sanofi Company Entities, (e.g., Sanofi Pasteur)

³ Collaboration (Shared) Funding – is the full amount of a grant funded under an agreement with Regeneron, some or all of which may be shared between the collaborating entities.

⁴ Collaboration (Shared) Funding – is the full amount of a grant funded under an agreement with Lexicon, some or all of which may be shared between the collaborating entities.

Independent Medical Education Grants

1st Oct 2018 – 31st Dec 2018

| Recipient Name(s) ¹ | Activity Title | Funding Amount ² |
|---|--|-----------------------------|
| UMA MLG, LLC | A Virtual Reality Experience - Pediatric Atopic Dermatitis: Treatment and Management | 230,950 |
| UMA MLG, LLC | A Virtual Reality View - Long-term Management of Atopic Dermatitis: New and Emerging Targeted Systemic Therapies | 449,550 |
| UMA Education, Inc. dba Global Education Group Integritas Communications | Clinical Issues in Atopic Dermatitis: Discussions and Debates on Improving Outcomes for Moderate-to Severe Disease | 168,203 |
| National Kidney Foundation | Evidence-Based New Insights on the Management of Fabry Disease | 145,000 |
| UMA Education Inc., dba Global Education Group Integritas Communications | Looking Ahead: Optimizing Management Strategies in Moderate-to-Severe Atopic Dermatitis | 393,362 |
| Postgraduate Healthcare Education, LLC Postgraduate Institute for Medicine (PIM) | Type 1 Gaucher Disease: Optimizing Treatment and Management Approaches | 63,950 |
| The France Foundation | Severe Asthma Science: Endotypes and Precision Medicine Presidential Case Studies | 292,680 |
| UMA Education, Inc dba Global Education Group Integritas Communications | Clearing the Air in Severe Asthma Management: Improving Patient Outcomes Through Shared Clinical Decision Making | 549,981 |
| AKH Inc. Advancing Knowledge in Healthcare Tarsus Cardio dba South Beach Symposium | Masters of Pediatric Dermatology | 20,000 |
| PRIME Education, LLC | Atopic Dermatitis Across the Life Cycle: Taking the Long View on Diagnostic, Treatment, and Management Strategies | 199,700 |

¹ Applicant names are provided by the requestor. If applicants apply as a group for a single educational activity; all applicants may not be identified above. The Company funds other educational activities (including fellowships and non-physician and patient education); all of which do not appear on this report, but appear on other reports on this site.

² “Funding Amount” is the amount that the Company funded during Q4, 2018 identified above based upon an agreement. Recipients are required to return any unused funds. Information on unused funds returned by the applicant on activities are not reported. “Funding Amount” does not include funds that may have been provided by other affiliated Sanofi Company Entities, (e.g., Sanofi Pasteur)

³ Collaboration (Shared) Funding – is the full amount of a grant funded under an agreement with Regeneron, some or all of which may be shared between the collaborating entities.

⁴ Collaboration (Shared) Funding – is the full amount of a grant funded under an agreement with Lexicon, some or all of which may be shared between the collaborating entities.

Independent Medical Education Grants

1st Oct 2018 – 31ST Dec 2018

| Recipient Name(s) ¹ | Activity Title | Funding Amount ² |
|--|---|-----------------------------|
| PRIME Education, LLC | Linking Patients, Providers, and Payers in Coordinated Approaches to Severe Asthma Treatment | 316,500 |
| AKH Inc., Advancing Knowledge in Healthcare Tarsus Cardio | 17th Annual South Beach Symposium | 20,000 |
| PRIME Education, LLC | Stepping Up Managed Care and Specialty Pharmacy Decision-Making to Support Integration of New Evidence and Mechanisms in Asthma Treatment | 499,075 |
| Academy of Managed Care Pharmacy (AMCP) | AMCP Specialty Connect - Focus on Gene Therapy | 35,000 |
| UMA MLG, LLC | The Unique Role of the Community Pharmacist in the Management of Moderate-to-Severe Atopic Dermatitis in the Pediatric Population | 199,550 |
| Rush University Medical Center Plexus Communications | Applying the Latest Clinical Data and Emerging Therapeutic Approaches in the Management of Prostate Cancer Throughout the Disease Spectrum | 60,000 |
| Purdue University College of Pharmacy PVI, PeerView Institute for Medical Education, Inc. | PeerView Live, "Unraveling the Complexities of Prostate Cancer Management: Focus on Therapeutic Decisions for Early Stage Disease and the Implications for Later Stage Disease" | 109,387 |
| Rush University Medical Center Plexus Communications | Community Uro-Oncology Forums: Understanding the Disease Continuum and Navigating the Evolving Treatment Paradigms in Prostate Cancer | 80,000 |
| American Health Resources, LLC | Updates in Myeloma Therapeutics: Bone Health, Smoldering Disease, and CAR-T Cells | 8,000 |

¹ Applicant names are provided by the requestor. If applicants apply as a group for a single educational activity; all applicants may not be identified above. The Company funds other educational activities (including fellowships and non-physician and patient education); all of which do not appear on this report, but appear on other reports on this site.

² "Funding Amount" is the amount that the Company funded during Q4, 2018 identified above based upon an agreement. Recipients are required to return any unused funds. Information on unused funds returned by the applicant on activities are not reported. "Funding Amount" does not include funds that may have been provided by other affiliated Sanofi Company Entities, (e.g., Sanofi Pasteur)

³ Collaboration (Shared) Funding – is the full amount of a grant funded under an agreement with Regeneron, some or all of which may be shared between the collaborating entities.

⁴ Collaboration (Shared) Funding – is the full amount of a grant funded under an agreement with Lexicon, some or all of which may be shared between the collaborating entities.

Independent Medical Education Grants

1st Oct 2018 – 31st Dec 2018

| Recipient Name(s) ¹ | Activity Title | Funding Amount ² |
|--|--|-----------------------------|
| Siyemi Learning | Action Eczema: Global Atopic Dermatitis Educational Resource Center | 383,320 |
| ScientiaCME | Genetic Disorders: Updates from The 15th Annual World Symposium | 17,800 |
| NERGG, Inc. | NERGG 2018 Annual Meeting | 6,000 |
| UMA MLG, LLC | The CATALYST Initiative – A 3D View - Targeting Inflammatory Cytokines: Addressing Articular and Systemic Pathology in Patients with Moderate-to-Severe Rheumatoid Arthritis | 348,275 |
| University of Nevada, Reno School of Medicine Foundation for Research and Education in Dermatology | 2018 Fall Clinical Dermatology Conference® and Beyond: Practical Approaches to Patient Management – Focus on Atopic Dermatitis | 150,000 |
| Trustees of Boston University Talem Health, LLC | Talem ACO Summit Series - Atopic Dermatitis: Improving Outcomes Through a Patient-Centered Approach | 198,555 |
| Cleveland Clinic Educational Foundation | 7th Annual Basic & Clinical Immunology for the Busy Clinician | 15,000 |
| University of Nebraska Medical Center The Board of Regents of the University of Nebraska dba the University of Nebraska Medical Center | Rural Health Summit Series: Updates in Atopic Dermatitis for the Rural Primary Care Physician | 201,343 |
| International Eczema Council | Atopic Dermatitis Phenotypes and Biomarkers | 11,500 |
| Excel Continuing Education | Fabry Disease: Role of the Genetic Counselor in an Ever-Changing Landscape; The Role of the Genetic Counselor in Pompe Disease | 81,900 |
| Specialty Pharma Education Center | Advancing Care in Prostate Cancer: Clinical Understandings & Evolving Treatment and Management Approaches | 49,750 |

¹ Applicant names are provided by the requestor. If applicants apply as a group for a single educational activity; all applicants may not be identified above. The Company funds other educational activities (including fellowships and non-physician and patient education); all of which do not appear on this report, but appear on other reports on this site.

² “Funding Amount” is the amount that the Company funded during Q4, 2018 identified above based upon an agreement. Recipients are required to return any unused funds. Information on unused funds returned by the applicant on activities are not reported. “Funding Amount” does not include funds that may have been provided by other affiliated Sanofi Company Entities, (e.g., Sanofi Pasteur)

³ Collaboration (Shared) Funding – is the full amount of a grant funded under an agreement with Regeneron, some or all of which may be shared between the collaborating entities.

⁴ Collaboration (Shared) Funding – is the full amount of a grant funded under an agreement with Lexicon, some or all of which may be shared between the collaborating entities.

Independent Medical Education Grants

1st Oct 2018 – 31st Dec 2018

| Recipient Name(s) ¹ | Activity Title | Funding Amount ² |
|---|--|-----------------------------|
| Massachusetts Eye And Ear Infirmary, Department of Otolaryngology President and Fellows of Harvard College | Surgery of the Thyroid and Parathyroid Glands | 15,000 |
| Rush University Medical Center Plexus Communications | VHA UroOncology Clinical Forums “Advancing Strategies in Prostate Cancer: Individualizing Treatment Plans Based on the Rapidly Evolving Landscape and Disease Continuum”. | 90,000 |
| Physicians' Education Resource, LLC (PER) | “D” is for Diagnosis: Solving the Mystery of Lysosomal Storage Disorders | 100,000 |
| Muscular Dystrophy Association | Medical Education Tactics for the Physician and Care Center Community: Hot Topics in NMD Webcast and MDA Speaker Slides | 211,525 |
| Med-IQ, Inc. | Bridging the Gap Between Research and Clinical Advances in Gaucher Disease Type 3 | 245,887 |
| Medical Education Resources, Inc. Impact Education, LLC | Managing Multiple Sclerosis: A Guide for Specialty Pharmacy Professionals | 75,000 |
| Med Learning Group | A Multiple Sclerosis Virtual Reality Experience: Reaching Diagnosis, Delivering Treatment, and Setting Goals for Long-Term Success | 50,000 |
| Integrity Continuing Education, Inc. | 2019 AAFP State Society CME Meetings and BioDigital Human On-demand Simulation Activity - Ensuring Early Diagnosis and Targeting Treatment to Remission in Patients with Rheumatoid Arthritis: Recommendations for Primary Care Clinicians | 299,000 |

¹ Applicant names are provided by the requestor. If applicants apply as a group for a single educational activity; all applicants may not be identified above. The Company funds other educational activities (including fellowships and non-physician and patient education); all of which do not appear on this report, but appear on other reports on this site.

² “Funding Amount” is the amount that the Company funded during Q4, 2018 identified above based upon an agreement. Recipients are required to return any unused funds. Information on unused funds returned by the applicant on activities are not reported. “Funding Amount” does not include funds that may have been provided by other affiliated Sanofi Company Entities, (e.g., Sanofi Pasteur)

³ Collaboration (Shared) Funding – is the full amount of a grant funded under an agreement with Regeneron, some or all of which may be shared between the collaborating entities.

⁴ Collaboration (Shared) Funding – is the full amount of a grant funded under an agreement with Lexicon, some or all of which may be shared between the collaborating entities.

Independent Medical Education Grants

1st Oct 2018 – 31ST Dec 2018

| Recipient Name(s) ¹ | Activity Title | Funding Amount ² |
|--|---|-----------------------------|
| Yale School of Medicine | 2019 Update: What's New in the Field of Multiple Sclerosis | 15,000 |
| Annenberg Center for Health Sciences at Eisenhower Academy for Continued Healthcare Learning | 11th Annual Linda Morgante MS Nurse Leadership Program | 45,000 |
| Physicians' Education Resource, LLC (PER) | 2019 ACTRIMS: An Interactive, Case-Based Discussion: Interpreting the Therapeutic Landscape in Multiple Sclerosis | 212,000 |
| The Medical College of Wisconsin, Inc. Carden Jennings Publishing Co., Ltd. | 29th Annual International Prostate Cancer Update (IPCU 29) | 15,000 |
| UMA MLG, LLC | In Pursuit of the Best Outcomes in Rheumatoid Arthritis: Inhibiting Inflammatory Pathology | 194,680 |
| NJ State Society of Physician Assistants College of Saint Elizabeth | Focus on the Future | 21,000 |
| Postgraduate Institute for Medicine Enquiring Minds, LLC | Lysosomal Storage Disorders - Common Presetations of Uncommon Diseases: Expert Guidance on Early Identification and Therapeutic Optimization | 99,885 |
| Greenwood Genetic Center | Spring 2019 and Spring 2020 educational program: Enhancing genetic understanding of lysosomal storage diseases for practicing Physician Assistants (PA) and PA students | 82,003 |

¹ Applicant names are provided by the requestor. If applicants apply as a group for a single educational activity; all applicants may not be identified above. The Company funds other educational activities (including fellowships and non-physician and patient education); all of which do not appear on this report, but appear on other reports on this site.

² "Funding Amount" is the amount that the Company funded during Q4, 2018 identified above based upon an agreement. Recipients are required to return any unused funds. Information on unused funds returned by the applicant on activities are not reported. "Funding Amount" does not include funds that may have been provided by other affiliated Sanofi Company Entities, (e.g., Sanofi Pasteur)

³ Collaboration (Shared) Funding – is the full amount of a grant funded under an agreement with Regeneron, some or all of which may be shared between the collaborating entities.

⁴ Collaboration (Shared) Funding – is the full amount of a grant funded under an agreement with Lexicon, some or all of which may be shared between the collaborating entities.

Independent Medical Education Grants

1st Oct 2018 – 31st Dec 2018

| Recipient Name(s) ¹ | Activity Title | Funding Amount ² |
|---|---|---------------------------------------|
| ThinkGenetic Foundation | Closing the Genetics Gap: A Lecture for Healthcare Advocates on Lysosomal Storage Diseases Designed to Increase Access to Genetics Services in Medically Underserved Parishes of Louisiana | 9,320 |
| National Association for Continuing Education | Conversations in Primary Care 2019 Live Virtual Symposium Series Individualizing Asthma Care: Addressing Type 2 Inflammation | 64,000 |
| Excel Continuing Education | Newborn Screening for Fabry Disease: What Neonatologists and Pediatricians Needs to Know | 86,735 |
| Excel Continuing Education | Exploring the Genetic Counselor's Role in Gaucher Disease (satellite symposium at NSGC) | 42,330 |
| Mayo Clinic Arizona | Mayo Clinic 2019 Multiple Sclerosis & Autoimmune Neurology Update | 7,500 |
| UT Southwestern Medical Center | 41st Annual Carrell Krusen Neuromuscular Symposium | 5,000 |
| Medscape LLC | Improving Appropriate Use of PCSK9 Inhibitors in Interventional Cardiology: Patient-Centered Care Perspectives Post-MI | 736,125 Collaboration ³ |
| Postgraduate Institute for Medicine | The iQ&A Case-by-Case, PCSK9 Cardiovascular Medicine Intelligence zone: from trials to treatment—How Do Recent Guidelines and CV Outcome Trials Help Identify High Risk Patients (Elevated LDL-C, Recent ACS, Advanced ASCVD, PCI, Statin Intolerance and Resistance, and Diabetes) Who Are Optimal Candidates for PCSK9 Inhibitor-Mediated Therapy | 488,000 Collaboration ³ |

¹ Applicant names are provided by the requestor. If applicants apply as a group for a single educational activity; all applicants may not be identified above. The Company funds other educational activities (including fellowships and non-physician and patient education); all of which do not appear on this report, but appear on other reports on this site.

² "Funding Amount" is the amount that the Company funded during Q4, 2018 identified above based upon an agreement. Recipients are required to return any unused funds. Information on unused funds returned by the applicant on activities are not reported. "Funding Amount" does not include funds that may have been provided by other affiliated Sanofi Company Entities, (e.g., Sanofi Pasteur)

³ Collaboration (Shared) Funding – is the full amount of a grant funded under an agreement with Regeneron, some or all of which may be shared between the collaborating entities.

⁴ Collaboration (Shared) Funding – is the full amount of a grant funded under an agreement with Lexicon, some or all of which may be shared between the collaborating entities.